Focusing on the initiation of treatment for newly diagnosed patients with CML, Jorge E. Cortes, MD, details important factors to consider when starting treatment and Claire Saxton discusses strategies ...
Tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment, offering more effective and better-tolerated options than previous therapies. Second- and third-generation TKIs address resistance ...
CHICAGO — Asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia, according to study results presented at ASCO ...
Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival. When imatinib (Gleevec; Novartis), the first-ever tyrosine kinase inhibitor, made its ...
In Canada, Scemblix ® was previously approved for the treatment of adult patients with Ph+ CML-CP previously treated with two or more TKIs. Newly diagnosed patients will now have access to a treatment ...
MONTREAL, Dec. 10, 2025 /CNW/ - Novartis Canada is pleased to announce that Scemblix ® (asciminib) is one of the first therapies to be prioritized for public reimbursement under Ontario's new Funding ...
Preclinical data shows TERN-701's superior potency against CML resistance mutations; early clinical trial results indicate promising patient responses. Terns Pharmaceuticals announced promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results